Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I; Multi-Center; Open-Label (Parts 1 and 2); Randomized, Double-Blind, Placebo-Controlled (Part 3); Single-Dose; 3-Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese Subjects in Fasted and Fed States

Next Previous
X
Search
Trial Profile

A Phase I; Multi-Center; Open-Label (Parts 1 and 2); Randomized, Double-Blind, Placebo-Controlled (Part 3); Single-Dose; 3-Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese Subjects in Fasted and Fed States

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gepotidacin (Primary) ; Mesylates
  • Indications Bacterial infections; Gonorrhoea; Skin and soft tissue infections; Urinary tract infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Jan 2023 Results assessing the pharmacokinetics and interethnic comparisons of oral gepotidacin (free-base and to-be-marketed mesylate formulations) administered as single doses ranging from 1500 to 3000 mg in fed and fasted states, and as 2 x 3000-mg doses given 12 hours apart under fed conditions in healthy participants of Japanese ancestry from NCT02853435 and NCT04493931 studies, published in the Clinical Pharmacology in Drug Development.
    • 11 Oct 2021 Results assessing pharmacokinetics and safety of Gepotidacin (GSK2140944) in healthy adult and adolescent participants from NCT02853435 and NCT04079790 trials, published in the Antimicrobial Agents and Chemotherapy.
    • 23 Nov 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top